share_log

Piper Sandler Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19

Moomoo 24/7 ·  Mar 14 10:26

Piper Sandler analyst Joseph Catanzaro maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $18 to $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment